A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.
A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?
A study of patients with bone marrow failure (BMF) and short telomeres found that a conditioning regimen that eliminates radiation and DNA-alkylating agents led...
The significance of JAK2-positive test results in a healthy patient
This month Josef Prchal, MD, discusses the significance of JAK2-positive test results in a healthy patient.
And don't forget to check out next month's clinical dilemma...
The significance of JAK2-positive test results in a healthy patient
Here’s how readers responded to a You Make the Call question about the significance of JAK2-positive test results in a healthy patient..
Disclaimer: ASH does...
Tagraxofusp-erzs Becomes First Approval for BPDCN
The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...
Transplant or No Transplant for Older, Fit Patients With MDS?
Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with advanced myelodysplastic syndromes (MDS), compared with OS in patients...
An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML
According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...
Luspatercept Reduces the Need for Transfusions in Patients With Beta Thalassemia and MDS
In two separate phase III trials presented at the 2018 ASH Annual Meeting, luspatercept, a first-in-class recombinant fusion protein, was found to be safe...
Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models
Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...
How I Treat in Brief: Using Molecular Genetic Tests to Evaluate Myelodysplastic Syndromes
David P. Steensma, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, discussed how to use results from molecular genetic tests in...
No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS
In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...
